Tactogen is a pharmatech startup with a mission to provide safe, effective prescription mental wellness for everyone. Founded in 2020 by Genentech data science leader and PhD neuroscientist Matthew Baggott and deeptech serial entrepreneur Luke Pustejovsky, the company is focused on developing the next generation of MDMA-like medicines. Their compounds aim to facilitate psychotherapy, decision-making, and psychological growth, with the goal of enabling safer take-home prescription empathogens. Tactogen's IP includes novel molecules, drug discovery methods, and pharmaceutical preparations, all geared towards making mental wellness more effective and accessible.
The company has attracted attention from investors, with its Seed Round investment in January 2022 being backed by Noetic Fund and PsyMed Ventures. Tactogen operates within the Biopharma, Biotechnology, and Pharmaceutical industries and is headquartered in the United States. With its innovative approach to mental wellness and strong backing from notable investment firms, Tactogen is poised to make significant strides in reshaping the landscape of mental healthcare.
